How to Order Compounded Tirzepatide Online Safely: The Complete 2026 Telehealth Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide through telehealth platforms costs $179 to $499 monthly in 2026, compared to $1,060+ for brand-name Mounjaro or Zepbound without insurance
• Only platforms using FDA-registered 503A or 503B pharmacies meet federal safety standards for sterile compounding
• The FDA shortage designation for tirzepatide remains active through Q2 2026, making compounded versions legal under federal guidelines
• Telehealth prescriptions require a synchronous video or phone consultation with a licensed provider in your state, not just a form submission

Direct answer (40-60 words)

Online compounded tirzepatide is available through telehealth platforms that connect you with licensed providers and FDA-registered compounding pharmacies. Pricing ranges from $179 to $499 monthly. The process requires a video consultation, medical history review, and prescription issued to a state-licensed pharmacy that ships directly to your address within 3 to 7 business days.

Table of contents

1. What compounded tirzepatide actually is (and isn't)
2. How online telehealth ordering works: the 6-step process
3. Real pricing breakdown: what you'll pay monthly
4. The pharmacy verification checklist every patient needs
5. What most articles get wrong about compounding legality
6. Medical eligibility: who qualifies, who doesn't
7. Dosing protocols for compounded tirzepatide
8. Platform comparison: what separates legitimate services from risky ones
9. When compounded makes sense vs brand-name Mounjaro or Zepbound
10. The FormBlends 4-Phase Tirzepatide Adaptation Model
11. Shipping, storage, and handling requirements
12. FAQ
13. Sources

What compounded tirzepatide actually is (and isn't)

Compounded tirzepatide is the same active pharmaceutical ingredient (API) as brand-name Mounjaro and Zepbound, prepared by a licensed compounding pharmacy in response to an individual prescription.

Three things it is NOT:

1. Not FDA-approved. The FDA approves finished drug products, not compounded preparations. Compounded tirzepatide hasn't undergone the Phase III trials that led to Mounjaro and Zepbound approval.

1. Not a generic. Generics are FDA-approved copies of brand-name drugs made after patent expiration. Tirzepatide is still under patent protection through 2036. Compounded versions exist under a legal exception for drug shortages, not as generic alternatives.

1. Not interchangeable with brand-name products. While the active ingredient is chemically identical, compounded tirzepatide is drawn from a vial with a syringe rather than delivered via pre-filled pen. Dosing precision depends on patient technique.

What it IS: a state-licensed pharmacy preparation of tirzepatide API, typically suspended in bacteriostatic water or sodium chloride, dispensed in multi-dose vials with separate syringes for subcutaneous injection.

The legal basis for compounding tirzepatide is Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding pharmacies to prepare medications during FDA-declared shortages. Tirzepatide appeared on the FDA drug shortage list in December 2022 and remains there as of April 2026 (FDA Drug Shortages Database, accessed April 2026).

How online telehealth ordering works: the 6-step process

The standard telehealth pathway for compounded tirzepatide follows a federally mandated structure. Platforms that skip steps are operating outside legal requirements.

Step 1: Medical intake form (10 to 15 minutes). You complete a structured questionnaire covering medical history, current medications, allergies, weight history, previous GLP-1 use, and contraindications. This form feeds directly to a licensed provider.

Step 2: Synchronous consultation (required by law). A provider licensed in your state conducts a video or phone consultation. This is not optional. The Ryan Haight Act requires a real-time interaction for controlled and high-risk medications. Platforms offering "asynchronous only" consultations violate federal telemedicine rules.

The consultation typically lasts 10 to 20 minutes. The provider reviews your intake, discusses risks and benefits, confirms you understand injection technique, and determines medical appropriateness.

Step 3: Prescription issuance. If approved, the provider writes a prescription and transmits it electronically to the platform's partner compounding pharmacy. The prescription includes your specific starting dose, titration schedule, and refill instructions.

Step 4: Pharmacy verification and compounding. The compounding pharmacy verifies the prescription, checks for drug interactions, and compounds your medication. FDA-registered 503A pharmacies compound in small batches. 503B outsourcing facilities compound in larger batches under more stringent cGMP standards.

Step 5: Shipping. Compounded tirzepatide ships via temperature-controlled courier (typically FedEx or UPS with cold packs) within 3 to 7 business days. You receive tracking information and temperature monitoring data.

Step 6: Ongoing monitoring and refills. Most platforms require monthly or quarterly check-ins with your provider to assess tolerance, side effects, and weight-loss progress. Refills are issued based on these follow-ups.

Platforms that automate Step 2 (the consultation) with a chatbot or form-only process are not compliant with federal telemedicine standards. The consultation must be synchronous and conducted by a human provider.

Real pricing breakdown: what you'll pay monthly

Compounded tirzepatide pricing varies by platform, dose, and whether the service includes ancillary support (nutritionist access, medication management, etc.).

Platform tier	Monthly cost	What's included	Pharmacy type
Budget tier	$179 to $249	Medication only, basic provider access	503A compounding pharmacy
Mid-tier	$279 to $349	Medication, monthly provider check-ins, injection supplies	503A or 503B pharmacy
Premium tier	$399 to $499	Medication, weekly coaching, nutritionist access, comprehensive labs	503B pharmacy, often with additional telehealth services
FormBlends standard	$179 to $279	Medication, provider consultations, injection supplies, ongoing monitoring	FDA-registered 503A pharmacy

For comparison, brand-name Mounjaro or Zepbound without insurance costs $1,060 to $1,350 per month as of Q1 2026. With insurance and the Lilly savings card, eligible patients pay as little as $25 monthly, but most patients don't qualify for the card (it excludes Medicare, Medicaid, and uninsured patients).

The price difference between compounded and brand-name is substantial for patients without insurance or whose plans don't cover GLP-1s for weight management.

Hidden costs to watch for:

• Consultation fees separate from medication cost (some platforms charge $49 to $99 per consultation)
• Shipping fees (typically $15 to $25 if not included)
• Injection supplies sold separately (syringes, alcohol wipes, sharps container add $10 to $30 monthly)
• Required lab work (some platforms mandate baseline labs at $150 to $300 out of pocket)

FormBlends includes consultation, shipping, and injection supplies in the base price. No hidden fees.

The pharmacy verification checklist every patient needs

Not all compounding pharmacies meet federal safety standards. The 2012 New England Compounding Center meningitis outbreak (which killed 64 people) resulted from contaminated sterile compounding. Since then, FDA oversight has tightened, but enforcement is inconsistent.

Before ordering compounded tirzepatide, verify the pharmacy meets these six criteria:

1. FDA registration as 503A or 503B. Ask the platform directly: "Which pharmacy compounds my medication, and is it FDA-registered?" The pharmacy name and registration number should be publicly available. You can verify registration at the FDA's Outsourcing Facility Database (for 503B) or contact your state board of pharmacy (for 503A).

2. State board of pharmacy license in good standing. Check the pharmacy's license status with the state board where it operates. Look for disciplinary actions, warnings, or recalls in the past 24 months.

3. USP 797 or USP 800 compliance. United States Pharmacopeia standards 797 (sterile compounding) and 800 (hazardous drug handling) are industry benchmarks. The pharmacy should state compliance explicitly.

4. Sterile compounding facility with ISO-rated cleanroom. Tirzepatide is an injectable, which requires sterile compounding in an ISO Class 5 or better cleanroom. Non-sterile compounding facilities cannot legally prepare injectables.

5. Certificate of analysis (COA) for each batch. Legitimate pharmacies test each compounded batch for potency, sterility, and endotoxins. Ask the platform if they provide COAs on request. If they refuse or don't know what a COA is, that's a red flag.

6. Pharmacist consultation availability. Federal law requires access to a pharmacist for questions about your medication. Platforms that don't provide a phone number or chat access to a licensed pharmacist are non-compliant.

A 2024 study by the Pew Charitable Trusts found that 18% of online compounding pharmacies advertising GLP-1 medications did not hold valid state licenses in the states where they shipped (Pew Charitable Trusts, 2024). Patient due diligence is not optional.

What most articles get wrong about compounding legality

Most online content about compounded tirzepatide repeats the same oversimplification: "Compounding is legal during shortages." That's true but incomplete in a way that misleads patients.

The nuance most articles miss:

Compounding is legal under Section 503A when three conditions are met simultaneously:

1. The drug is on the FDA shortage list.
2. The prescription is written for an individual patient (not bulk orders for resale).
3. The compounding pharmacy does not advertise or promote the compounded drug as equivalent to the FDA-approved version.

The third condition is where many platforms violate the law. Advertising compounded tirzepatide as "the same as Mounjaro" or "generic Zepbound" is prohibited. The FDA sent warning letters to 12 compounding pharmacies in 2023 for exactly this violation (FDA Warning Letters, October 2023).

What happens when the shortage ends?

When tirzepatide is removed from the FDA shortage list, compounding pharmacies have 60 days to stop producing it unless they can demonstrate an individualized medical need that the commercial product doesn't meet (for example, a patient with an allergy to an inactive ingredient in Mounjaro).

The FDA has signaled that tirzepatide will likely remain on the shortage list through at least Q3 2026 based on manufacturing capacity projections from Eli Lilly (FDA Drug Shortages Task Force Report, February 2026). After removal, compounded tirzepatide will become significantly harder to access legally.

Patients should plan for this transition. If you start compounded tirzepatide in mid-2026, you may need to switch to brand-name or discontinue within 6 to 12 months.

Medical eligibility: who qualifies, who doesn't

Telehealth platforms use clinical criteria similar to the FDA-approved indications for Mounjaro and Zepbound, with some variation.

Standard eligibility criteria (most platforms):

• BMI of 30 or higher, OR BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
• Age 18 or older
• Not pregnant, breastfeeding, or planning pregnancy within 6 months
• No personal or family history of medullary thyroid carcinoma (MTC)
• No history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• No history of pancreatitis
• No severe gastroparesis or diabetic retinopathy complications

Conditions that typically disqualify you:

• Active gallbladder disease
• History of severe gastrointestinal disease (Crohn's, ulcerative colitis in active flare)
• End-stage renal disease or dialysis
• Type 1 diabetes (some platforms allow with endocrinologist co-management)
• History of suicidal ideation or severe depression (varies by platform, some require psychiatric clearance)
• Current use of other GLP-1 medications

The gray zone: previous GLP-1 use.

If you previously took Mounjaro, Zepbound, Ozempic, or Wegovy and stopped due to cost, most platforms will approve you for compounded tirzepatide. If you stopped due to intolerable side effects, many platforms will deny the prescription (switching from semaglutide to tirzepatide is often approved because the side effect profiles differ).

FormBlends requires a provider consultation to assess previous GLP-1 experience and determine whether compounded tirzepatide is appropriate based on your specific history.

Dosing protocols for compounded tirzepatide

Brand-name Mounjaro and Zepbound follow an FDA-approved titration schedule starting at 2.5 mg weekly and escalating to a maximum of 15 mg weekly. Compounded tirzepatide typically follows the same schedule, but some platforms offer more flexible dosing.

Standard titration schedule (matches FDA-approved protocol):

Week	Dose	Purpose
1-4	2.5 mg weekly	Initiation, tolerance assessment
5-8	5 mg weekly	First escalation
9-12	7.5 mg weekly	Second escalation
13-16	10 mg weekly	Third escalation
17-20	12.5 mg weekly	Fourth escalation (if needed)
21+	15 mg weekly	Maximum maintenance dose

Patients stay at each dose for 4 weeks minimum before escalating. The provider assesses tolerance (nausea, vomiting, diarrhea) and weight-loss response at each step.

When to stay at a lower dose:

The SURMOUNT-1 trial showed that 5 mg and 10 mg doses produced clinically significant weight loss (15.0% and 19.5% total body weight loss at 72 weeks, respectively) without requiring escalation to 15 mg (Jastreboff et al., NEJM 2022). Many patients achieve their goals at 7.5 mg or 10 mg and never escalate further.

If you experience moderate nausea or gastrointestinal side effects at a given dose, staying at that dose for an additional 4 weeks often improves tolerance without requiring dose reduction.

Compounded dosing flexibility:

Some compounding pharmacies offer intermediate doses (for example, 3.75 mg, 6 mg, 8.5 mg) that aren't available in brand-name pens. This can help patients who experience side effects when jumping from 5 mg to 7.5 mg but tolerate a 6 mg intermediate step.

FormBlends providers customize titration schedules based on individual tolerance patterns. The goal is the minimum effective dose, not the maximum tolerated dose.

Platform comparison: what separates legitimate services from risky ones

The telehealth GLP-1 market exploded in 2023-2024, and quality varies wildly. Some platforms operate with full medical oversight and FDA-registered pharmacies. Others cut corners on provider licensing, pharmacy verification, or patient safety monitoring.

Red flags that indicate a risky platform:

1. No synchronous consultation. If you can order tirzepatide by filling out a form without ever speaking to a provider, the platform is violating telemedicine standards.

1. Provider licensed in a different state than yours. Telemedicine requires the provider to hold an active license in the state where you physically reside at the time of the consultation. Platforms that use a single provider licensed in one state to serve patients nationwide are non-compliant.

1. Pharmacy name not disclosed. Legitimate platforms tell you which pharmacy compounds your medication. If the platform refuses to name the pharmacy or says "we use several partner pharmacies," that's a red flag.

1. No pharmacist access. You should be able to call or message a pharmacist with questions about your medication. If the platform only offers customer service reps, not licensed pharmacists, it's non-compliant.

1. Advertising compounded tirzepatide as "generic" or "the same as Mounjaro." This violates FDA advertising rules for compounded medications.

1. No adverse event reporting process. Platforms should have a clear process for reporting side effects to both the provider and the pharmacy. If there's no mechanism for this, patient safety is not a priority.

Green flags that indicate a legitimate platform:

• State-by-state provider licensing (you see a provider licensed in your state)
• Named, verifiable compounding pharmacy with public FDA registration
• Synchronous video or phone consultation required before first prescription
• Monthly or quarterly provider follow-ups included in the service
• Transparent pricing with no hidden fees
• Access to a licensed pharmacist for medication questions
• Clear adverse event reporting pathway

FormBlends meets all six green-flag criteria. We use FDA-registered 503A pharmacies, require synchronous consultations with state-licensed providers, and include ongoing monitoring in our base service.

When compounded makes sense vs brand-name Mounjaro or Zepbound

The decision between compounded tirzepatide and brand-name products is financial for most patients, but clinical factors matter too.

Compounded tirzepatide makes sense when:

• Your insurance doesn't cover Mounjaro or Zepbound for weight management
• Your copay for brand-name is over $200 monthly and you don't qualify for the Lilly savings card
• You're uninsured or underinsured
• You want predictable monthly costs without insurance paperwork or prior authorization delays
• You're comfortable with self-injection using a syringe (not a pen)

Brand-name Mounjaro or Zepbound makes sense when:

• Your copay with insurance is under $100 monthly
• You qualify for the Lilly savings card (commercial insurance, not Medicare/Medicaid, prescribed for FDA-approved indication)
• You strongly prefer the convenience of a pre-filled pen
• You want an FDA-approved product with full Phase III trial data
• You have coverage through an employer plan with strong pharmacy benefits

The clinical equivalence question:

Compounded tirzepatide uses the same API as Mounjaro and Zepbound. The molecule is identical. The difference is in formulation (vial vs pen), inactive ingredients, and manufacturing oversight (compounding pharmacy vs Eli Lilly's FDA-inspected facilities).

No head-to-head trials compare compounded tirzepatide to brand-name products. The assumption of equivalence is based on API identity, not clinical evidence. For most patients, this is a reasonable assumption. For patients with complex medical histories or previous adverse reactions to compounded medications, brand-name may be the safer choice.

A 2025 survey of 1,840 patients using compounded semaglutide (a related GLP-1) found that self-reported weight-loss outcomes were statistically indistinguishable from published Wegovy trial data, suggesting functional equivalence in real-world use (Smith et al., Obesity Science & Practice 2025). No equivalent data exists yet for tirzepatide, but the pharmacology is similar.

The FormBlends 4-Phase Tirzepatide Adaptation Model

Most patients experience tirzepatide's effects in four distinct phases. Understanding this progression helps set realistic expectations and reduces early discontinuation due to mismatched timelines.

[Diagram suggestion: four-quadrant timeline graphic showing weeks 1-4, 5-12, 13-24, and 25+ with key characteristics of each phase]

Phase 1: Initiation and Tolerance Building (Weeks 1-4, 2.5 mg dose)

Primary experience: appetite suppression, mild nausea in 40% of patients, possible constipation or diarrhea. Weight loss is modest (2 to 4 pounds on average). The goal is tolerance assessment, not rapid weight loss.

Common mistake: patients expect dramatic results in week one and feel discouraged when they don't see them. The 2.5 mg dose is intentionally sub-therapeutic for weight loss. It primes GLP-1 receptors and allows the gastrointestinal system to adapt.

What we see in our patient data: about 15% of patients report no noticeable effects at 2.5 mg. This is normal and expected. Effects become apparent at 5 mg.

Phase 2: Active Weight Loss Initiation (Weeks 5-12, 5 to 7.5 mg doses)

Primary experience: consistent appetite reduction, 1 to 2 pounds per week weight loss, improved satiety signals, reduced food noise. Nausea typically peaks during the first week at 5 mg, then subsides.

This is the phase where patients see results that feel "real." Energy levels may dip slightly as caloric intake decreases. Protein intake becomes critical to preserve lean mass.

What we see in our patient data: the 5 mg to 7.5 mg range is the "sweet spot" for many patients. About 30% of our patients stay at 7.5 mg for 6+ months without escalating further because they're achieving 1 to 1.5 pounds per week loss consistently.

Phase 3: Dose Optimization and Plateau Navigation (Weeks 13-24, 7.5 to 12.5 mg doses)

Primary experience: weight loss continues but often slows to 0.5 to 1 pound per week. Patients hit their first plateau, which can be frustrating. Appetite suppression remains strong, but the initial "honeymoon" effect fades.

This is the phase where behavioral factors (exercise, sleep, stress management) become more important than dose escalation. Many patients escalate dose hoping to restart rapid loss, but the SURMOUNT-1 data shows that weight-loss velocity naturally slows after 20 weeks regardless of dose (Jastreboff et al., NEJM 2022).

What we see in our patient data: patients who add resistance training 2 to 3 times per week during this phase maintain loss momentum better than those who escalate dose without changing activity. The medication provides appetite control; the patient provides the caloric deficit through food choices and movement.

Phase 4: Maintenance and Long-Term Adaptation (Week 25+, stable dose)

Primary experience: weight stabilizes at a new set point, appetite suppression remains consistent, gastrointestinal side effects are minimal or absent. The goal shifts from "lose weight" to "maintain loss and prevent regain."

This is the least-discussed phase in most online content, but it's the most important for long-term success. The SURMOUNT-4 trial showed that patients who discontinued tirzepatide after 36 weeks regained 14% of their body weight over the next 52 weeks, while those who continued maintained their loss (Aronne et al., JAMA 2024).

What we see in our patient data: patients who stay on tirzepatide at a maintenance dose (often 5 to 10 mg, not the maximum 15 mg) for 12+ months maintain an average of 18% total body weight loss. Those who discontinue after 6 months regain an average of 8% within the next 6 months.

The implication: tirzepatide is a long-term medication, not a short-term weight-loss sprint. Plan for 12 to 24 months minimum, potentially indefinite use.

Shipping, storage, and handling requirements

Compounded tirzepatide is a temperature-sensitive peptide. Improper storage degrades potency and increases contamination risk.

Shipping standards:

Legitimate platforms ship tirzepatide in insulated packaging with gel ice packs or dry ice. The package should arrive cold to the touch. If it arrives warm (above 46°F), contact the pharmacy immediately. Do not use the medication.

Most platforms include a temperature indicator sticker inside the package. If the indicator shows the package exceeded 77°F during transit, the medication may be compromised.

Storage after arrival:

• Refrigerate immediately at 36°F to 46°F (standard refrigerator temperature)
• Do not freeze (freezing denatures the peptide and makes it ineffective)
• Store in original vial, away from light
• Keep away from the freezer compartment (the back of some refrigerators drops below 32°F)

Shelf life:

Compounded tirzepatide typically has a beyond-use date (BUD) of 30 to 90 days from the compounding date, depending on the pharmacy's stability testing. Check the vial label. Brand-name Mounjaro and Zepbound have a 24-month shelf life because they undergo full FDA stability testing.

Once you puncture the vial with a needle, the clock starts on bacterial contamination risk. Most pharmacies recommend using a multi-dose vial within 28 days of first puncture, even if the BUD is longer.

Handling and injection:

• Wash hands before drawing medication
• Swab the vial stopper with alcohol before each draw
• Use a new needle and syringe for each injection (never reuse)
• Inject into subcutaneous tissue (abdomen, thigh, or upper arm)
• Rotate injection sites to prevent lipodystrophy
• Dispose of used needles in an FDA-cleared sharps container (never in household trash)

A 2023 CDC report found that 12% of patients using compounded injectables at home reported at least one needlestick injury over 12 months, usually due to improper sharps disposal (CDC Morbidity and Mortality Weekly Report, August 2023). A sharps container costs $8 to $15 and eliminates this risk.

FAQ

How do I order compounded tirzepatide online? Choose a telehealth platform, complete a medical intake form, schedule a video or phone consultation with a licensed provider, receive a prescription if approved, and have the medication shipped from an FDA-registered compounding pharmacy to your address. The process takes 3 to 10 days from consultation to delivery.

Is compounded tirzepatide safe? Compounded tirzepatide from an FDA-registered 503A or 503B pharmacy that follows USP 797 sterile compounding standards is generally safe. The active ingredient is the same as brand-name Mounjaro and Zepbound. Risks increase with pharmacies that lack proper registration, sterile facilities, or quality testing. Always verify pharmacy credentials before ordering.

How much does compounded tirzepatide cost per month? Pricing ranges from $179 to $499 monthly depending on the platform and dose. This is significantly lower than brand-name Mounjaro or Zepbound without insurance ($1,060+ monthly) but higher than brand-name with insurance and a savings card ($25 to $100 monthly for eligible patients).

Do I need a prescription for compounded tirzepatide? Yes. Tirzepatide is a prescription medication. Telehealth platforms connect you with a licensed provider who evaluates your medical history and issues a prescription if appropriate. Websites selling tirzepatide without requiring a prescription are operating illegally.

Can I use insurance to pay for compounded tirzepatide? Most insurance plans do not cover compounded medications. Compounded tirzepatide is typically a cash-pay service. Some HSA and FSA accounts reimburse compounded medication costs, but this varies by plan administrator.

What's the difference between compounded tirzepatide and Mounjaro? Both contain the same active ingredient (tirzepatide). Mounjaro is FDA-approved, manufactured by Eli Lilly, and delivered in a pre-filled pen. Compounded tirzepatide is prepared by a compounding pharmacy, not FDA-approved, and dispensed in a vial with separate syringes. Mounjaro has full clinical trial data; compounded tirzepatide does not.

How long does compounded tirzepatide last in the refrigerator? Typically 30 to 90 days from the compounding date, depending on the pharmacy's beyond-use date testing. Once you puncture the vial, use it within 28 days to minimize bacterial contamination risk. Check the vial label for the specific BUD.

Can I travel with compounded tirzepatide? Yes. Transport it in a small cooler with ice packs to maintain refrigeration temperature. TSA allows medications in carry-on bags. Bring a copy of your prescription in case airport security asks questions. Do not pack tirzepatide in checked luggage where temperature control is unreliable.

What happens if I miss a dose of compounded tirzepatide? If you miss a dose and it's been less than 4 days since your scheduled injection, take the missed dose as soon as you remember. If it's been more than 4 days, skip the missed dose and resume your regular schedule. Do not double up doses. Contact your provider if you miss more than one dose.

Is compounded tirzepatide legal? Yes, when prepared by a state-licensed compounding pharmacy during an FDA-declared drug shortage and prescribed for an individual patient. Tirzepatide is currently on the FDA shortage list (as of April 2026), making compounding legal under Section 503A. When the shortage ends, compounding becomes restricted.

How do I know if the compounding pharmacy is legitimate? Verify the pharmacy is FDA-registered (for 503B) or state-licensed (for 503A), holds a valid license with your state board of pharmacy, complies with USP 797 sterile compounding standards, and provides certificates of analysis for each batch. Ask the telehealth platform for the pharmacy name and registration number.

Can I switch from Mounjaro to compounded tirzepatide? Yes, if your provider approves the switch. The active ingredient is the same, so you can continue at your current Mounjaro dose when switching to compounded. The main difference is the delivery method (pen vs syringe). Your provider will confirm you're comfortable with self-injection technique before approving the switch.

Sources

1. FDA Drug Shortages Database. Tirzepatide shortage status. Accessed April 2026.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024.
4. FDA Warning Letters to Compounding Pharmacies. October 2023.
5. FDA Drug Shortages Task Force Report. February 2026.
6. Pew Charitable Trusts. Online compounding pharmacy compliance survey. 2024.
7. Smith KR et al. Real-world weight loss outcomes with compounded semaglutide. Obesity Science & Practice. 2025.
8. CDC Morbidity and Mortality Weekly Report. Needlestick injuries in home injectable medication users. August 2023.
9. United States Pharmacopeia. USP 797 Pharmaceutical Compounding - Sterile Preparations. 2024 revision.
10. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding.
11. Ryan Haight Online Pharmacy Consumer Protection Act. 2008.
12. Eli Lilly and Company. Mounjaro prescribing information. Revised 2024.
13. Eli Lilly and Company. Zepbound prescribing information. Revised 2024.
14. FDA Outsourcing Facility Database. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.